4.6 (333) · $ 22.00 · In stock
Observed efficacy and clinically important improvements in participants with osteoarthritis treated with subcutaneous tanezumab: results from a 56-week randomized NSAID-controlled study, Arthritis Research & Therapy
The effects of intravenous infusion of autologous mesenchymal stromal cells in patients with subacute middle cerebral artery infarct: a phase 2 randomized controlled trial on safety, tolerability and efficacy - Cytotherapy
Jose HERNANDEZ, Associate Adjunct Professor
Atrial Fibrillation Treatment & Management: Approach Considerations, Risk-Management Decisions, Management of New-Onset AF
Life, Free Full-Text
Duration of Treatment With Nonsteroidal Anti-Inflammatory Drugs and Impact on Risk of Death and Recurrent Myocardial Infarction in Patients With Prior Myocardial Infarction
Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors vs. Dipeptidyl Peptidase-4 (DPP4) Inhibitors for New-Onset Dementia: A Propensity Score-Matched Population-Based Study With Competing Risk Analysis. - Abstract - Europe PMC
Jose HERNANDEZ, Associate Adjunct Professor
Time to first NSAID claim description by CV primary diagnosis at the
Observed efficacy and clinically important improvements in participants with osteoarthritis treated with subcutaneous tanezumab: results from a 56-week randomized NSAID-controlled study, Arthritis Research & Therapy
Observed efficacy and clinically important improvements in participants with osteoarthritis treated with subcutaneous tanezumab: results from a 56-week randomized NSAID-controlled study, Arthritis Research & Therapy
Long-Term Frequent Use of Non-Steroidal Anti-Inflammatory Drugs Might Protect Patients with Ankylosing Spondylitis from Cardiovascular Diseases: A Nationwide Case-Control Study
Explore PASI 90 and PASI 100 Response Rates